Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma

被引:18
|
作者
Boulin, Mathieu [1 ,2 ]
Adam, Heloise [1 ]
Guiu, Boris [2 ,3 ]
Aho, Ludwig Serge [4 ]
Cercueil, Jean-Pierre [2 ,3 ]
Di Martino, Cyrille [4 ]
Fagnoni, Philippe [1 ,2 ]
Minello, Anne [2 ,5 ]
Jouve, Jean Louis [2 ,5 ]
Hillon, Patrick [2 ,5 ]
Bedenne, Laurent [2 ,5 ]
Lepage, Come [2 ,5 ]
机构
[1] CHU Univ Hosp, Dept Pharm, F-21000 Dijon, France
[2] Univ Burgundy, F-21079 Dijon, France
[3] CHU Univ Hosp, Dept Radiol, F-21000 Dijon, France
[4] Georges Francois Leclerc Anticanc Ctr, Dept Pharm, F-21079 Dijon, France
[5] CHU Univ Hosp, Dept Hepatogastroenterol, F-21079 Dijon, France
关键词
Hepatocellular carcinoma; Toxicity; Transarterial chemoembolisation; LIPIODOL CHEMOEMBOLIZATION; COHORT; TRIAL; MODEL;
D O I
10.1016/j.dld.2013.12.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. Aim: To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC. Methods: All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade >= 4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic regression model. The robustness of the final model was confirmed using bootstrapping (500 replications). Results: 124 patients were included, median age was 67 years and 90% were male; 22 patients (18%) experienced severe TACE-related toxicity. Factors that independently predicted severe TACE-related toxicity in multivariate analysis were total tumour size (OR, 1.15 cm(-1); 95% CI, 1.04-1.26; p = 0.01), and high serum AST levels (OR, 1.10 per 10 IU/l; 95% CI, 1.01-1.21; p = 0.04). The results were confirmed by bootstrapping. Conclusions: Total tumour size and high serum AST levels were predictive factors of severe TACE-related toxicity in this hospital-based series of patients with unresectable HCC. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:358 / 362
页数:5
相关论文
共 50 条
  • [21] Prognostic factors for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolisation combined with radiotherapy
    Qi, Zhonghua
    Zhao, Qianqian
    Wang, Renben
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 (03) : 480 - 488
  • [22] Transarterial chemoembolisation using drug eluting beads for hepatocellular carcinoma
    Smith, B. W.
    Jeffrey, G. P.
    Macquillan, G. C.
    Tibballs, J.
    Ratman, L.
    Cherian, S.
    Ferguson, J.
    Adams, L. A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A307 - A308
  • [23] Paraplegia following transarterial chemoembolisation for hepatocellular carcinoma: a case report
    Lin, Gang-Hua
    Shih, Yu-Lueng
    ACTA CHIRURGICA BELGICA, 2021, 121 (06) : 437 - 440
  • [24] Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation
    Cabibbo, G.
    Genco, C.
    Di Marco, V.
    Barbara, M.
    Enea, M.
    Parisi, P.
    Brancatelli, G.
    Romano, P.
    Craxi, A.
    Camma, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (02) : 196 - 204
  • [25] TRANSARTERIAL CHEMOEMBOLISATION IN INOPERABLE HEPATOCELLULAR CARCINOMA: A TERTIARY CENTRE EXPERIENCE
    McMahon, M.
    Popuri, R. K.
    Chalmers, N.
    Prince, M. I.
    GUT, 2010, 59 : A74 - A74
  • [26] Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
    Oliveri, Roberto S.
    Wetterslev, Jorn
    Gluud, Christian
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (03):
  • [27] Analysis of prognostic factors in patients receiving transarterial radioembolization for unresectable hepatocellular carcinoma
    Soydal, Cigdem
    Araz, Mine
    Nak, Demet
    Akku, Pinar
    Baltacioglu, Muhammet Halil
    Bilgic, Sadik
    Kucuk, Nuriye Ozlem
    NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (01) : 73 - 77
  • [28] Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma
    Welker M.W.
    Zangos S.
    Kriener S.
    Mönch C.
    Zeuzem S.
    Trojan J.
    Journal of Gastrointestinal Cancer, 2010, 41 (2) : 149 - 152
  • [29] Transarterial chemoembolisation vs embolisation for hepatocellular carcinoma. A comparative audit
    Stigliano, R
    Morisco, F
    Chan, CW
    Cecilioni, L
    Leandro, G
    Burroughs, AK
    JOURNAL OF HEPATOLOGY, 2004, 40 : 83 - 83
  • [30] Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
    H. Perfahl
    H. V. Jain
    T. Joshi
    M. Horger
    N. Malek
    M. Bitzer
    M. Reuss
    Scientific Reports, 10